The public markets may have turned into a killing zone for biotechs and a harsh environment for tech stocks generally, but that doesn’t mean the big money has stopped flowing into some select global AI startups. Goldman Sachs took an unusual turn into the field this week, leading a $300 million round for a Beijing-based startup boasting of its muscle power on CRISPR gene editing while promising to use AI and robotics to redefine lab efficiency in creating new drugs with clients. Keep reading Endpoints with a free subscription Unlock this story instantly and join 143,900+ biopharma pros reading Endpoints...